Irinotecan

Irinotecan

SCHEMBL4034

CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TOP1

The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 known ✓ P11387 6/20 0.78
GLA P06280 2/20 1.00
GAA P10253 2/20 1.00
SLC22A2 O15244 1/20 1.00
SLC22A1 O15245 1/20 1.00
SLC22A3 O75751 1/20 1.00
MMP1 P03956 1/20 1.00
CHRM4 P08173 1/20 1.00
CYP3A4 P08684 1/20 1.00
ADRA2C P18825 1/20 1.00
ACHE P22303 1/20 1.00
SLC47A2 Q86VL8 1/20 1.00
SLC47A1 Q96FL8 1/20 1.00
KDM4E B2RXH2 1/20 0.99
ALDH1A1 P00352 1/20 0.99
LMNA P02545 1/20 0.99
HPGD P15428 1/20 0.99
SMN1; SMN2 Q16637 1/20 0.99
HSD17B10 Q99714 1/20 0.99
PAX8 Q06710 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Irinotecan SCHEMBL29367581 1.00 GLA (1.00) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL131381 1.00 GLA (1.00) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL19534323 1.00 GLA (1.00) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL29356918 1.00 GLA (1.00) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL13420262 1.00 GLA (1.00) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL12313065 1.00 GLA (1.00) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL1501486 0.99 GLA (0.99) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL4164613 0.99 GLA (0.99) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL5693425 0.99 PAX8 (0.99) GLAGAASLC22A2SLC22A1SLC22A3
Irinotecan SCHEMBL4450369 0.99 GLA (1.00) GLAGAASLC22A2SLC22A1SLC22A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 179248 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144793-A1 METHODS OF TREATING CANCER AMGEN INC. (US) 2026-05-28 US claimed
US-20260144890-A1 ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY MyricX Pharma Limited (GB) 2026-05-28 US claimed
US-20260144750-A1 Dosing Regimens for Treatment of Glioblastoma SIGNPATH PHARMA INC. (US) 2026-05-28 US claimed
US-20260144882-A1 ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF BIO-THERA SOLUTIONS, LTD. (CN) 2026-05-28 US claimed
EP-4746898-A2 IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2026-05-27 EP claimed
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
EP-4747388-A1 RECOMBINANT BACTERIAL CELL CAPABLE OF EXPRESSING A HETEROLOGOUS EXTRACELLULAR MATRIX (ECM) DEGRADING POLYPEPTIDE USING A TUMOUR-INDUCIBLE PROMOTER NEOBE THERAPEUTICS LTD (GB) 2026-05-27 EP claimed
EP-4748449-A2 USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION Temple University Of The Commonwealth System Of Higher Education (US) 2026-05-27 EP claimed
CN-122075411-A Tripterine liposome, its combined medicine and its application in preventing and treating tumor 2026-05-26 CN claimed
WO-1994005672-A1 PROCESS FOR PREPARING CERTAIN PYRROLO[3,4- b]QUINOLINES, CERTAIN 1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO[1,2-b]QUINOLIN-9(11H)-ONES SMITHKLINE BEECHAM CORPORATION (US) 1994-03-17 WO claimed
EP-0371169-B1 Method for controlling the taking over of, on the one hand, switching-related tasks and, on the other hand, operational and/or protection-related tasks by a processor in the central control unit of a telecommunications switching system SIEMENS AG (DE) 1994-02-16 EP claimed
EP-0350478-B1 PROCESS FOR OPERATING A MULTIPROCESSOR CENTRAL CONTROL UNIT OF A RELAY SYSTEM SIEMENS AG (DE) 1993-11-03 EP claimed
EP-0229851-B1 REGION MACHINING METHOD FANUC LTD. (JP) 1993-09-15 EP claimed
WO-1993009782-A1 COMBINATION CHEMOTHERAPY SMITHKLINE BEECHAM CORPORATION (US) 1993-05-27 WO claimed
CN-1016828-B CENTRAL CONTROL UNIT AND WORKING METHOD FOR EXCHANGE SYSTEM SIEMENS AG (DE) 1992-05-27 CN claimed
EP-0238841-B1 ERROR-PROTECTED MULTIPROCESSOR CONTROLLER HAVING A HIGH AVAILABILITY TO A SWITCHING SYSTEM, AND METHOD FOR MEMORY CONFIGURATION OPERATION OF THIS CENTRALLER SIEMENS AKTIENGESELLSCHAFT (DE) 1991-11-06 EP claimed
EP-0371169-A1 Method for controlling the taking over of, on the one hand, switching-related tasks and, on the other hand, operational and/or protection-related tasks by a processor in the central control unit of a telecommunications switching system SIEMENS AKTIENGESELLSCHAFT (DE) 1990-06-06 EP claimed
CN-87101839-A The central control unit of exchange system and the method that makes its work 1987-12-02 CN claimed
EP-0238841-A1 Error-protected multiprocessor controller having a high availability to a switching system, and method for memory configuration operation of this centraller SIEMENS AKTIENGESELLSCHAFT (DE) 1987-09-30 EP claimed